Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Equivalents (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Cash & Equivalents for 7 consecutive years, with $570.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 58.46% to $570.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $570.1 million through Dec 2025, up 58.46% year-over-year, with the annual reading at $570.1 million for FY2025, 58.46% up from the prior year.
  • Cash & Equivalents hit $570.1 million in Q4 2025 for BridgeBio Pharma, up from $283.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $749.0 million in Q2 2025 to a low of $180.3 million in Q3 2021.
  • Historically, Cash & Equivalents has averaged $418.4 million across 5 years, with a median of $400.6 million in 2021.
  • Biggest YoY gain for Cash & Equivalents was 283189.21% in 2021; the steepest drop was 50.85% in 2021.
  • Year by year, Cash & Equivalents stood at $393.8 million in 2021, then decreased by 4.34% to $376.7 million in 2022, then fell by 0.2% to $375.9 million in 2023, then decreased by 4.3% to $359.8 million in 2024, then soared by 58.46% to $570.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for BBIO at $570.1 million in Q4 2025, $283.3 million in Q3 2025, and $749.0 million in Q2 2025.